Canada's Theratechnologies says that a Phase III trial of its experimental HIV therapy hit its primary endpoint. TH9507, a therapy for HIV's side effects, demonstrated an average 15 percent reduction in visceral adipose tissue versus baseline and 20 percent reduction versus a placebo following 26 weeks of therapy. The trial goal was an eight percent reduction in visceral adipose tissue. Researchers say they hope to replicate those results in a new study scheduled to get underway in early 2007.
"The emerging efficacy/safety profile of TH9507 is exactly what we were hoping for," says CEO Yves Rosconi. "It has great prospects as a treatment for excess visceral fat accumulation in HIV patients, with potential advantages over other approaches being developed."
- here's the release [1] on the trial data
Links:
[1] http://www.fiercebiotech.com/node/4992